Vical Inc (VICL) 1.08 $VICL
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.08 (+0.03), NNVC: 2.80 (-0.07)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 3.22 (+0.07), VICL: 1.08 (+0.03), MRK: 57.72 (-1.62), GNCA: 8.31 (-0.10)
Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
GlobeNewswire - Thu Dec 11, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015.
VICL: 1.08 (+0.03)
Vical to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, December 2, at 1:30 p.m. ET at the Piper Jaffray 26 Annual Healthcare Conference (New York, December 2- 3). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Vical to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Tue Nov 11, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 - 19). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Vical's (VICL) CEO Vijay Samant on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 12:22AM CDT
VICL: 1.08 (+0.03)
Vical updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:34PM CDT
VICL: 1.08 (+0.03)
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the third quarter of 2013. Revenues for the third quarter of 2014 were $3.4 million, compared with revenues of $1.5 million for the third quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.08 (+0.03)
Vical EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:40AM CDT
VICL: 1.08 (+0.03)
SCG, CETV, VICL Expected To Be Down Before Next Earnings Releases
M2 - Mon Oct 27, 4:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. SCANA Corp (NYSE:SCG), Central European Media Enterprises Ltd (NASDAQ:CETV), Vical Inc (NASDAQ:VICL) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
VICL: 1.08 (+0.03), CETV: 2.70 (-0.01), SCG: 56.73 (-0.85)
Vical reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 12:12PM CDT
VICL: 1.08 (+0.03)
Vical Announces News Release and Conference Call Schedule for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and nine months ended September 30, 2014, before the opening of trading on Thursday, October 30, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, October 30. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 1.08 (+0.03)
HSV-2 Vaccine: Pharmaceutical Giant and Biotech Firm Join Forces; CBCD Commends Sanofi Pasteur (SNY) and Immune Design (IMDZ)
PRWeb - Tue Oct 21, 11:02PM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.08 (+0.03), IMDZ: 22.35 (-0.20), GSK: 42.42 (-0.93)
Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.08 (+0.03), ZIOP: 4.33 (+0.07), CELGZ: 3.51 (-0.03)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.08 (+0.03), EBS: 26.04 (-0.33), FCSC: 2.53 (+0.02), EPZM: 18.35 (-1.45)
Stock to Watch: Vical Up 15.1% (VICL)
Comtex SmarTrend(R) - Mon Oct 13, 11:37AM CDT
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 15.1% to $1.24 on 8.1x average daily volume. Vical has traded 3.7 million shares thus far today, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (15.1% to the Dow's -0.3%) and outperformed the S&P 500 (15.1% to the S&P's -0.5%) during today's trading.
VICL: 1.08 (+0.03)
Vical Granted Six U.S. Patents for HSV-2 Vaccines
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Vical Incorporated (Nasdaq:VICL) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.
VICL: 1.08 (+0.03)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 91.28 (+5.16), VICL: 1.08 (+0.03), SGMO: 16.53 (+2.46)
Vical to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, September 10, at 10:00 a.m. ET at the Rodman & Renshaw 16th Annual Global Investment Conference (New York, September 8 - 10). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
VICL: 1.08 (+0.03), PACB: 6.81 (+0.04), LXRX: 0.85 (-0.05), TMO: 124.99 (-1.73), JAZZ: 165.12 (-8.09)
Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 1.08 (+0.03), NNVC: 2.80 (-0.07)
Agenus: Herpes Competition And Cancer Checkpoint Prospects
William Meyers - at Seeking Alpha - Thu Dec 11, 11:06AM CST
AGEN: 3.22 (+0.07), VICL: 1.08 (+0.03), MRK: 57.72 (-1.62), GNCA: 8.31 (-0.10)
Vical Completes Enrollment in Its Therapeutic HSV-2 Vaccine Clinical Trial
GlobeNewswire - Thu Dec 11, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), the predominant cause of recurrent genital herpes. The enrollment was completed on schedule as originally planned. The randomized, double-blind, placebo-controlled trial will evaluate safety, tolerability and efficacy of two vaccine candidates (one encoding glycoprotein D alone and the other in combination with UL46). The study is powered to show at least a 30% decrease in the viral shedding rate following 3 doses of vaccine. A total of 165 otherwise healthy HSV-2- infected patients aged 18 to 50 years were enrolled across seven U.S. trial sites. The Company expects to release efficacy data by the middle of 2015.
VICL: 1.08 (+0.03)
Vical to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, December 2, at 1:30 p.m. ET at the Piper Jaffray 26 Annual Healthcare Conference (New York, December 2- 3). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Vical to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Tue Nov 11, 8:00PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, November 18, at 4:10 p.m. ET at the Stifel 2014 Healthcare Conference (New York, November 18 - 19). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Vical's (VICL) CEO Vijay Samant on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 12:22AM CDT
VICL: 1.08 (+0.03)
Vical updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:34PM CDT
VICL: 1.08 (+0.03)
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the third quarter of 2013. Revenues for the third quarter of 2014 were $3.4 million, compared with revenues of $1.5 million for the third quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. for development and manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.08 (+0.03)
Vical EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:40AM CDT
VICL: 1.08 (+0.03)
SCG, CETV, VICL Expected To Be Down Before Next Earnings Releases
M2 - Mon Oct 27, 4:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. SCANA Corp (NYSE:SCG), Central European Media Enterprises Ltd (NASDAQ:CETV), Vical Inc (NASDAQ:VICL) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
VICL: 1.08 (+0.03), CETV: 2.70 (-0.01), SCG: 56.73 (-0.85)
Vical reports October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 12:12PM CDT
VICL: 1.08 (+0.03)
Vical Announces News Release and Conference Call Schedule for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and nine months ended September 30, 2014, before the opening of trading on Thursday, October 30, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, October 30. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 1.08 (+0.03)
HSV-2 Vaccine: Pharmaceutical Giant and Biotech Firm Join Forces; CBCD Commends Sanofi Pasteur (SNY) and Immune Design (IMDZ)
PRWeb - Tue Oct 21, 11:02PM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.08 (+0.03), IMDZ: 22.35 (-0.20), GSK: 42.42 (-0.93)
Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.08 (+0.03), ZIOP: 4.33 (+0.07), CELGZ: 3.51 (-0.03)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.08 (+0.03), EBS: 26.04 (-0.33), FCSC: 2.53 (+0.02), EPZM: 18.35 (-1.45)
Stock to Watch: Vical Up 15.1% (VICL)
Comtex SmarTrend(R) - Mon Oct 13, 11:37AM CDT
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 15.1% to $1.24 on 8.1x average daily volume. Vical has traded 3.7 million shares thus far today, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (15.1% to the Dow's -0.3%) and outperformed the S&P 500 (15.1% to the S&P's -0.5%) during today's trading.
VICL: 1.08 (+0.03)
Vical Granted Six U.S. Patents for HSV-2 Vaccines
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Vical Incorporated (Nasdaq:VICL) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.
VICL: 1.08 (+0.03)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 91.28 (+5.16), VICL: 1.08 (+0.03), SGMO: 16.53 (+2.46)
Vical to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, September 10, at 10:00 a.m. ET at the Rodman & Renshaw 16th Annual Global Investment Conference (New York, September 8 - 10). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.08 (+0.03)
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
VICL: 1.08 (+0.03), PACB: 6.81 (+0.04), LXRX: 0.85 (-0.05), TMO: 124.99 (-1.73), JAZZ: 165.12 (-8.09)
